Raymond James lowered the firm’s price target on DexCom (DXCM) to $81 from $83 and keeps a Strong Buy rating on the shares. Despite a high bar, results exceeded expectations and reinforced a double-digit growth trajectory driven by accelerating revenue, record new user additions, modest share gains, and strong margins and cash flow, with upcoming type 2 diabetes reimbursement expansion expected to act as a key catalyst, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target raised to $100 from $95 at Canaccord
- DexCom price target lowered to $67 from $72 at Barclays
- Buy Rating Reaffirmed on Dexcom as Margin Strength and Global Patient Growth Offset U.S. CGM Concerns; Price Target Reset to $75
- Closing Bell Movers: Apple higher after stronger than expected guidance
- DexCom affirms FY26 revenue $5.16B-$5.25B, consensus $5.23B